Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BioCardia ( (BCDA) ) is now available.
On September 18, 2025, BioCardia announced the pricing of a public offering of 4,800,000 shares of common stock and short-term warrants, expected to raise $6 million upfront with potential additional proceeds of $6 million if warrants are fully exercised. The proceeds are intended for working capital and advancing biotherapeutic candidates, with H.C. Wainwright & Co. acting as the exclusive placement agent.
The most recent analyst rating on (BCDA) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on BioCardia stock, see the BCDA Stock Forecast page.
Spark’s Take on BCDA Stock
According to Spark, TipRanks’ AI Analyst, BCDA is a Neutral.
BioCardia’s overall stock score is low due to significant financial challenges, negative technical indicators, and poor valuation metrics. While there are positive developments in clinical trials and regulatory progress, these are overshadowed by financial instability and bearish market momentum.
To see Spark’s full report on BCDA stock, click here.
More about BioCardia
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. The company offers biotherapeutic platforms such as CardiAMP autologous and CardiALLO allogeneic cell therapies, supported by its Helix biotherapeutic delivery and Morph vascular navigation product platforms.
Average Trading Volume: 324,428
Technical Sentiment Signal: Sell
Current Market Cap: $8.92M
For detailed information about BCDA stock, go to TipRanks’ Stock Analysis page.